A Resource for Collaborative Biologics Development in the NIH Intramural Program: NIH–Pfizer CTI Partnership

Authors

• Sitta Sittampalam
• Lili Portilla
• Anna Rossoshek
• Balki Balakrishnan
• Nicol Spears
• Geoff Spencer
• Cindy McConnell
• Chris Austin
• Anton Simeonov

Abstract

The recently established NIH-Pfizer Centers for Therapeutic Innovation (CTI) collaborative program is designed to help bridge the gap between early scientific discovery and its translation into new medicines through novel public-private partnerships. The CTI network includes 25 academic institutions, four patient foundations, and now NIH. NIH intramural researchers selected for CTI projects will have identified disease-related pathways or mechanisms as potential therapeutic targets that culminate in Phase I clinical trials to demonstrate proof-of-mechanism. NIH’s successful IRP applicants will have access to Pfizer biologics, therapeutics development and clinical expertise and the opportunity for IRP investigators to develop biologics against targets of interest, as well as invaluable training in state-of-the-art biologics development. Furthermore, any collaborative research performed at the NIH’s IRP laboratory will be funded by Pfizer, leading to a lower risk and significant leveraging of existing resources. The therapeutic modalities delivered by the collaboration include but are not limited to monoclonal antibodies, bispecific antibodies, antibody fragments (Fab, scFv), nanobodies, and antibody-drug conjugates, with projects expected to move into clinical development if pre-clinical development milestones are met. An overview of the CTI collaborative program will be provided, along with specific information on how IRP scientists can apply to access this novel resource.

Scientific Focus Area: Research Support Services

This page was last updated on Friday, March 26, 2021